Clinical trial
Therapeutic Safety and Efficacy of REP 9AC (REP 2055) in HBV or HCV Infected Patients
NCT02646163 is registered in ClinicalTrials.gov with Replicor Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Therapeutic Safety and Efficacy of REP 9AC (REP 2055) in HBV or HCV Infected Patients
- Lead sponsor
- Replicor Inc.
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- January 31, 2009
- Completion date
- December 31, 2012
- Enrollment
- 8 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.